Cargando…
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
BACKGROUND: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric can...
Autores principales: | Matsumoto, Toshihiko, Yamamura, Shogo, Ikoma, Tatsuki, Kurioka, Yusuke, Doi, Keitaro, Yasuda, Tomoyo, Boku, Shogen, Kawai, Takashi, Shibata, Nobuhiro, Nagai, Hiroki, Tsuduki, Takao, Shimada, Takanobu, Matsumoto, Yusuke, Tsumura, Takehiko, Takatani, Masahiro, Yasui, Hisateru, Satake, Hironaga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666830/ https://www.ncbi.nlm.nih.gov/pubmed/36408335 http://dx.doi.org/10.1177/11795549221137135 |
Ejemplares similares
-
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022) -
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
por: Matsumoto, Toshihiko, et al.
Publicado: (2023) -
Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
por: Matsumoto, Toshihiko, et al.
Publicado: (2023) -
Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
por: Ikoma, Tatsuki, et al.
Publicado: (2022) -
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)